KARACHI: IBL HealthCare Limited (PSX: IBLHL) reported a strong financial performance for the third quarter ended March 31, 2026, posting a significant increase in profitability driven by higher sales and improved operational efficiency. The company’s Board of Directors approved the financial results in its meeting held on April 28, 2026, while announcing no cash dividend, bonus shares, or any other corporate action.
During the quarter, the pharmaceutical company recorded net sales of Rs1.213 billion, up from Rs948.03 million in the corresponding period last year, reflecting a growth of nearly 28%. Gross profit also improved substantially to Rs442.82 million, compared with Rs313.30 million a year earlier.
Profit before taxation surged to Rs133.10 million, compared with Rs53.64 million in the same quarter of the previous year. After accounting for taxation, profit after tax climbed to Rs61.89 million, representing an increase of approximately 75% from Rs35.44 million recorded in the third quarter of FY2025.
Earnings per share (EPS) for the quarter rose to Rs0.63, compared with Rs0.36 in the corresponding quarter last year, highlighting the company’s improved profitability.
For the nine-month period ended March 31, 2026, IBL HealthCare posted revenue of Rs3.305 billion, compared with Rs3.145 billion in the same period last year. Gross profit increased to Rs1.245 billion, while profit before tax reached Rs331.27 million, up from Rs227.80 million.
Net profit for the nine-month period stood at Rs167.49 million, compared with Rs135.47 million in the corresponding period of FY2025, reflecting a year-on-year growth of nearly 24%. Earnings per share for the period improved to Rs1.70, versus Rs1.37 a year earlier.
The company’s financial position also strengthened during the period, with total assets increasing to Rs4.34 billion as of March 31, 2026, compared with Rs4.01 billion at the end of June 2025. Shareholders’ equity rose to approximately Rs2.49 billion, supported by higher retained earnings and the issuance of bonus shares during the period.
Despite reporting improved earnings, the Board decided not to recommend any cash dividend, bonus shares, right shares, or other corporate actions for the quarter. The company stated that the complete quarterly report will be transmitted through PUCARS within the prescribed timeframe.
